TP53 and breast carcinoma: In the United Kingdom, it is estimated that 6% of women with breast cancer under age 31 years carry TP53 mutations, and based on this evidence, a prevalence of 1/10,000 to 1/25,000 live births harboring pathogenic mutations was estimated [8].